RPL17 and melanoma: In a retrospective study which included 60 NRAS mutation and 169 NRAS‐wildtype melanoma patients, the NRAS mutation cohort showed a particularly marked benefit from anti‐PD‐1/PD‐L1 than wild type (clinical benefit rate, 73% vs. 35%).